Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial

Affiliations

• ¹ Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland.
• ² Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
• ³ Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
• ⁴ Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
• ⁵ Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
• ⁶ Biontech Innovative Manufacturing Services, Idar-Oberstein, Germany.
• ⁷ Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
• ⁸ Department of Immunology, University Hospital Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
• ⁹ Faculty of Medicine, University of Basel, Basel, Switzerland; Onkozentrum Zürich, Swiss Tumor Immunology Institute, Zurich, Switzerland.
• ¹⁰ Faculty of Medicine, University of Zurich, Zurich, Switzerland; Onkozentrum Zürich, Swiss Tumor Immunology Institute, Zurich, Switzerland.
• ¹¹ Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland; Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland. Electronic address: [email protected].